NCT05922839View on ClinicalTrials.gov

Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 11, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
DRUG

Zanubrutinib

Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months, and for effective patients, continue to use for 2 years after achieving optimal therapeutic effect.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Chen Miao

OTHER